Rob has worked in securities law, corporate finance, venture capital and mergers & acquisitions since 1998. Prior to joining THP, he worked at Citigroup Global Markets in healthcare investment banking and acquisition finance. Previously, Rob worked at the Securities & Exchange Commission and the law firm of Cravath, Swaine & Moore. Rob also served as a Peace Corps Volunteer in the Dominican Republic. Rob represents THP on the boards of EditCo, ETHERFAX, Frontier Psychiatry, InvisALERT, and Promptly. He previously served on the boards of Aquaro Histology, Grayhawk Health, TrakCel, Medpricer (acquired by Premier), Nimble Therapeutics (acquired by AbbVie), Nivagen (acquired by PAI Pharma), Verogen (acquired by QIAGEN) Akoya Biosciences (acquired by Quanterix), Freedom Innovations (acquired by Health Evolution Partners) and Specific Diagnostics (acquired by bioMérieux). Rob received a BS in Geological Sciences and a BA in Economics from UCSB. He received a JD/MBA from Northwestern University School of Law and Kellogg School of Management.